Effectiveness and safety of ledipasvir and sofosbuvir for patients infected with HCV genotype 1 in clinical practices

Effectiveness and safety of ledipasvir and sofosbuvir for patients infected with HCV genotype 1 in clinical practices - Ledipasvir and sofosbuvir treatment for HCV genotype 1 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024007

Enrollment

1000

Registered

2016-09-12

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C genotype 1

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic HCV genotype 1 infection

Exclusion criteria

Exclusion criteria: (1)Decompensated cirrhosis (Child B/C) (2)Autoimmune hepatitis or primary biliary cholangiris (3)eGFR<30 (4)Positivity for antibody to HIV

Design outcomes

Primary

Measure	Time frame
Rates of Sustained virological response at 12 weeks after the end of treatment	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results